key: cord-0917069-2ehgtlio
authors: Rusk, Debra S.; Strachan, Christian C.; Hunter, Benton R.
title: Lack of immune response after mRNA vaccination to SARS‐CoV‐2 in a solid organ transplant patient
date: 2021-05-03
journal: J Med Virol
DOI: 10.1002/jmv.27044
sha: d64cac72d20e60a2503da68c44f308688c9db478
doc_id: 917069
cord_uid: 2ehgtlio

The recent approval and distribution of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been a major development in the fight against the current coronavirus disease 2019 (COVID‐19) pandemic. The first two vaccines approved in the United States, mRNA‐1273, and BNT162b2, are both messenger RNA (mRNA) based and highly effective in immunocompetent persons, but efficacy in patients on immunosuppressants has not been established. Additionally, data suggests these patients are less likely than immunocompetent people to develop neutralizing antibodies after COVID‐19 infection. Given the high risk of poor outcomes in organ transplant and immunosuppressed patients, effective vaccination is paramount in this group. We present the first reported case of a solid organ transplant patient who failed to achieve seroconversion after two doses of mRNA vaccine. This case has significant implications about how immunosuppressed patients should be counseled about SARS‐CoV‐2 vaccination and the protection provided. Physicians should remain clinically suspicious for infection with SARS‐CoV‐2 despite vaccination status in solid organ transplant patients.

The recent approval and distribution of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been a major development in the fight against the current coronavirus disease 2019 (COVID-19) pandemic. The first two vaccines approved in the United States, mRNA-1273, and BNT162b2, are both messenger RNA (mRNA) based and highly effective. In Phase 3 trials, the two agents led to a 94% decrease in symptomatic COVID-19 cases, including severe cases. 1, 2 In Phase 2 trials, measured immunogenicity was universally induced in otherwise healthy adults, including the elderly. 3, 4 Patients on immunosuppressant medications have been generally excluded from the trials upon which approval of these vaccines are based. 5 Based on prior experience with other vaccines, it is possible that severely immunocompromised hosts and those with diminished protective responses may be less able to form appropriate immune responses to vaccination, 6 potentially diminishing or even eliminating the protective effect against SARS-CoV-2. This could have serious implications for these patients and those close to them. We present the first reported case of a solid organ transplant (SOT) patient who failed to achieve seroconversion after two doses of mRNA vaccine. 

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

An mRNA vaccine against SARS-CoV-2-preliminary report

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer, and liver transplant recipients

Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review

COVID-19 and solid organ transplantation: a review article

COVID-19 infection in kidney transplant recipients at the epicenter of pandemics

COVID-19 in liver transplant recipients: the French SOT COVID registry

Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients

Early development and durability of SARS-CoV-2 antibodies among solid organ transplant recipients: a pilot study

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection

How to cite this article: Rusk DS, Strachan CC, Hunter BR. Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient

The authors declare that there is no conflict of interests.

http://orcid.org/0000-0002-5924-3854Christian C. Strachan https://orcid.org/0000-0003-0143-6001Benton R. Hunter http://orcid.org/0000-0003-1141-8907